Sunday, May 18, 2025

Conflicts of Interest 3 Covid Crimes

 page1image715871312page1image194527088page1image715872560page1image715873392 page1image715872768page1image715873808 page1image715873600page1image715874016 page1image715874224page1image715874432

#EXIT

page1image715874640 page1image715874848

PANDEMIC

TERAY

page1image715875264 page1image715875472

INTERNATIONAL

page1image715875680

HEALTH REGULATIONS

page2image128819968

3

Covid Crimes

page2image178466800page2image128820304page2image128823440page2image178454528
page3image715860752 page3image715860960 page3image715861168

a

Fudging

the

Stats

page3image715861376 page3image194523728 page3image715862000 page3image715862208 page3image715862416 page3image715862624 page3image715862832 page3image715863040 page3image715863248 page3image715863456 page3image715863664 page3image715863872 page3image194519808page3image715865328 page3image715865536page3image715865744 page3image715825696 page3image715825488 page3image194518688 page3image715824864
page4image194711376page4image194722912

b

Pandemic Transmission Model - Neil Ferguson and the WHO’s Monstrous LIE

page4image194719888

Prof Neil Ferguson

Imperial College, London

page4image194718880

That Started it All

https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf

c

Neil Ferguson – A Monumental Fraud of Monstrous Proportions

Table: Performance of Imperial College Modelling in 4 Non-Lockdown Countries & the United States

page5image194712944page5image194710928

https://www.aier.org/article/the-failure-of-imperial-college-modeling-is-far-worse-than-we-knew/

page6image194717312page6image194715968page6image714556640

d

page6image194721008

For 6% of the deaths, COVID-19 was the only cause mentioned

page6image194712048 page6image194723360page6image194716528 page6image194720336

https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?fbclid=IwAR3-wrg3tTKK5-9tOHPGAHWFVO3DfslkJ0KsDEPQpWmPbKtp6EsoVV2Qs1Q#Comorbidities

e

The Crime of the...

HEALTHY

page7image128502624 page7image513787728 page7image128503408page7image128511808 page7image128514720 page7image128501168 page7image513797088 page7image128501504 page7image128509456 page7image513798336 page7image513798544
page8image714994688 page8image714995104page8image714990736 page8image714990944 page8image194674688 page8image194679840

i

The fEAR Porn. The LIES. The More LIES. THe cON

ii

page8image714989072

Asymptomatic = Sick Syndrome

https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmitted

page9image194685216

f

The Rap Sheet expands...

page9image714946160 page9image714945952 page9image714945744 page9image714945536 page9image714945328 page9image714943872page9image714944912 page9image714944704 page9image714944496 page9image714944288 page9image714944080 page9image714942208 page9image714942416 page9image714943456 page9image714943248 page9image714943040 page9image714942832 page9image714942624 page9image714935968 page9image714935136 page9image714935344 page9image714934720 page9image714934928 page9image714932432 page9image714932640 page9image714934512 page9image714934304 page9image714934096 page9image714933888 page9image714933680 page9image714933472 page9image714933264
page10image194562688

The Mask Fiasco

page10image715809312

Jun, 5, 2020

“The WHO has also updated their guidelines, for use of masks by the general public, ..., in light of evolvingevidence, WHO advises governments to encourage the general public to wear masks....”

page10image715809728

January, 22, 2021

“There is no scientific medical reason for any healthy person to wear a mask outside of a hospital. If you have no respiratory symptoms, such as, fever, cough or runny nose, you do not need to wear a medicalmask.”

g

The Banality of ...

page11image194574000 page11image194565712 page11image714455056page11image714455264

....Not Saving Lives as Treatment

page12image194561232

WHO has fallen victim to neoliberal globalization

Sent: Monday, January 22, 2007 4:29 PM Subject: Open letter to Dr Chan

"Academic institutions . . . have become businesses in their own right, seeking to commercialize for themselves research discoveries rather than preserve their independent scholarly status"

Alison Katz, IndependentWHO

http://www.next-up.org/pdf/AlisonKatzOpenLetterMargaretChanWHO.pdf

page13image194561456page13image194573664page13image714412304 page13image714412512page13image714412720 page13image194562576
page14image194527232

LancetNEJMGate: Fraudulent Study Retracted

Findings
We were unable to confirm a benefit of hydroxychloroquine or chloroquine,

when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.

The Lancet study based on data analysis of 96,032 patients hospitalized with COVID-19 between Dec 20, 2019, and April 14, 2020 from 671 hospitals Worldwide. The database was fabricated and the findings was based on completely fake figures and test trials.

The Study which killed the Hydroxychloroquine cure was essentially a colossal:

Fraud

page14image194533728

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31180-6.pdf

LancetNEJMGate: Fraudulent Study Retracted

page15image714388480page15image714388688page15image714388896

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269709/

https://www.thegatewaypundit.com/2020/06/exclusive-lancet-study-hydroxychloroquine- complete-fraud-authors-linked-pharmaceutical-industry-people-died-lies/

page16image194538320page16image714362320

The Lancet Study’s entire purpose was therefore to lie about Hydroxychloroquine in order to promote more expensive pharmaceutical alternatives.

page16image194534960

LancetNEJMWHOGate: WHO responds

page17image715069120

WHO pauses Hydroxychloroquine Arm of Covid-19 Clinical Trial – After Lancet Study finds higher Mortality Rate among patients taking the drug

page17image715074736

“In light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be "a temporary pause" on the hydroxychloroquine arm of its global clinical trial.

Tedros Adhanom Ghebreyesus WHO Director-General

26.05.2020 https://www.newindianexpress.com/world/2020/may/25/who-study-into-experimental-covid-19-treatments-pauses-testing-on-trumps-drug-hydroxychloroquine-2147914.html

"Hydroxychloroquine does not result in the reduction of mortality of hospitalized COVID-19 patients," the WHO reported (Solidarity Trial)

Hydroxychloroquine and Role as COVID-19 prophylaxis

page18image714372096
page19image714349680

Is in on the Fraud

page19image714350096page19image714350304

15 October 2020

Interim results from the Solidarity Therapeutics Trial, coordinated by the World Health Organization, indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among 14 200 hospitalized patients.

Trial 14 200 hospitalized patients, 52 countries, 200 hospitals, 2000 researchers

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments https://www.who.int/news/item/15-10-2020-solidarity-therapeutics-trial-produces-conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19-in-record-time

Drugs to prevent Covid-19

Living Guide

24th March 2023

page20image194529136

Table: Characteristics and outcomes of the RCTs evaluating hydroxychloroquine

Outcome

Intervention Impact of Hydroxychloroquine

Mortality

3 per 1000 Little or no effect on mortality

Admission to Hospital

1 per 1000 Little or no effect on hospital admission

Laboratory-confirmed SARS-CoV-2 infection

59 per 1000 Little or no effect on preventing infection

Adverse events leading to discontinuation

28 per 1000 A small increase in adverse effects leading to discontinuation

Recommendations

The panel felt that further research was unlikely to uncover a subgroup of patients that benefit from hydroxychloroquine, therefore recommends against the use of hydroxychloroquine as a prophylaxis

WHO Therapeutics Steering Committee

https://apps.who.int/iris/bitstream/handle/10665/366530/WHO-2019-nCoV-prophylaxes-2023.1-eng.pdf

page21image194697904

And then of course there was the...

in

fiasco...

I

v

ecm

page21image194698240 page21image714835584 page21image194697456 page21image714836624

e

page21image714836832
page22image714819616page22image714819408

trial : Dr Andrew Hill – Conflicts of Interest Consultant

page22image194710032 page22image194722800page22image194715632 page22image714822112 page22image714822320 page22image714822528 page22image194723696 page22image194714400 page22image194719104page22image194715744 page22image194714288 page22image194723248 page22image714825856 page22image194716416 page22image194719664 page22image194722688 page22image194721568page22image714827728 page22image194708128 page22image714828352 page22image714828560 page22image714828768 page22image194720112 page22image194716640 page22image714829808 page22image714830016page22image194716864 page22image714830640 page22image714830848 page22image194715408 page22image714831472 page22image714831680 page22image714831888 page22image194720672 page22image194720000page22image194708240 page22image194719776 page22image714801152 page22image714801360 page22image194722128 page22image194708912page22image194718320 page22image194710480 page22image194709248 page22image194713840page22image714804272

$50 million

Advisor to Bill and Melinda Gates Foundation

$40 million

Centre of Excellence for Long- acting Therapeutics (CELT)

Funders

page22image714804480 page22image714804688 page22image714804896 page22image714805104 page22image714805312page22image714805520 page22image714805728 page22image714805936

Dr. Andrew Hill

Senior Visiting Research Fellow Dept Pharmacology

Advisor

Previous employment Developer of antivirals

page22image194713504 page22image714806560 page22image714806768 page22image714806976 page22image194720784page22image714807600 page22image714807808
page22image194717648page22image194708576page22image194718096
page22image194713392
page22image194710256
page22image194719552

HIV Collaborative Fund

page22image194716192

PEPFAR

page22image194711712
page22image194707904page22image194682640
page22image194679952 page22image714814256 page22image714814464 page22image714814672 page22image194680848page22image714815296 page22image714815504

Consultant

E D I T O R

page22image194685776 page22image714816752 page22image194686000 page22image714784768 page22image714784976 page22image714785184 page22image714785392 page22image194684432page22image714786224
page23image513684688page23image513683024

trial : Dr Andrew Hill – Conflicts of Interest

page23image513683232

During the interview, Dr Hill admits that his funder, UNITAID influenced his conclusions to the aforementioned paper.

Four days before publication, Hill’s sponsor Unitaid gave the University of Liverpool, Hill’s employer $40 million.

4th March 2022

Controversial Journal Article

Meta-analysis of randomized trials of Ivermectin to treat SARS-CoV-2 infection

Hill, A et.al. Research Square, 19 Jan 2021

Results

Ivermectin was associated with reduced inflammation, faster viral clearance. Ivermectin showed significantly shorter duration of hospitalization, and in moderate or severe infection, there was a 75% reduction in deaths, with favourable clinical recovery and reduced hospitalization.

Conclusions

Not yet a sufficiently robust evidence base to justify the use or regulatory approval of ivermectin. However...clear need for additional, higher-quality and larger-scale clinical trials, warranted to investigate the use of ivermectin further.

Funder

page23image127393664

https://www.oraclefilms.com/alettertoandrewhill https://worldcouncilforhealth.org/multimedia/dear-andy-dr-tess-lawrie/ https://www.researchsquare.com/article/rs-148845/v1

page24image714849728page24image714849936

trial Dr Andrew Hill – Conflicts of Interest

page24image714817536

https://www.worldtribune.com/researcher-andrew-hills-conflict-a-40-million-gates-foundation-grant-vs-a-half-million-human-lives/

page25image715003584page25image715003376

: Dr Andrew Hill/Prof Andrew Owen – Conflicts of Interest

page25image715003168 page25image715002960 page25image715006288 page25image194550112page25image715007120
page25image194545744page25image194552352page25image194557280
page25image715010448page25image194557616

Nitazoxanide

AGILE Clinical Team

Funders

page25image194550560 page25image194557952 page25image194547648 page25image194558624 page25image194551456 page25image194555488page25image194553136 page25image194545632
page25image714720272 page25image714720480 page25image714720896

Scientific Advisor COVID-19 Guideline Development Group

page25image714721104 page25image714721312 page25image714721520 page25image714721728 page25image714721936 page25image714722560 page25image714722768page25image194547088 page25image714723392 page25image714723600 page25image714723808 page25image714724016page25image714724224 page25image714724432 page25image194544848 page25image714725056 page25image714725264

Professor Andrew Owen

Editor of Andrew Hill paper on Ivermectin

Professor of Pharmacology & Therapeutics

£2.2 million

Scientific Advisor

page25image714725472 page25image194551904 page25image714726512page25image194550448 page25image194559744 page25image714727552 page25image714727760 page25image714727968 page25image714728176 page25image714728384page25image714728592 page25image714728800

Principal Investigator

page25image194545520

£3million

page25image714729424 page25image714729632 page25image714729840

Funding Partners

page25image194544512

Co-Director Centre of Excellence in Long-acting Therapeutics (CELT)

page25image194556608
page25image714733376 page25image714733584 page25image194547424 page25image194556160 page25image714735040 page25image714735248page25image714702848 page25image194557504 page25image714703680

Remdesivir

Solid Drug Nanoparticle technology

VIR-7831 and VIR-7832, novel therapies COVID owned by

Lead Molnupiravir Trial

page25image714703888 page25image714704096 page25image714704304 page25image714704512 page25image714704720

Consultant

Director & CSO & shareholder

page26image194553584page26image715099392page26image715099600

: Dr Andrew Hill/Prof Andrew Owen – Conflicts of Interest

https://rairfoundation.com/deadly-cover-up-who-buried-the-research-proving-ivermectin-saves-covid-patients-lives/

World Crime Organization....Not Saving Lives as Treatment

page27image194550784 page27image194556832page27image194554480 page27image194555712page27image194553248page27image715004000

https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials

page28image714922080 page28image714922288page28image714922496page28image714922704

May, 2021

page29image714660768

bans IVERMECTIN

page29image714660976page29image714661184

https://www.sahpra.org.za/wp-content/uploads/2020/12/22-December-2020-Ivermectin.pdf

Ivermectin for COVID-19: real-time meta analysis of 99 studies

page30image715080512 page30image194620240page30image715091744 page30image715093824

Relative Risk

Analysis

Oct 2023

page30image715094032 page30image715094240page30image715094448 page30image715094656 page30image715094864

Primary Outcome 52% 99 Ventilation 29% 18 Hospitalisation 34% 29 Cases 81% 16 RCTs 55% 46 Prophylaxis 85% 17 Late Treatment 41% 45

137,686 33,157 44,784 13,696 11,855 19,764 59,776

page30image715095072 page30image715095280 page30image715095488 page30image715095696page30image714659936 page30image714659312 page30image714659520 page30image714659104page30image714995520 page30image714995936 page30image714997392 page30image714997184page30image714964992

c19ivm.org

https://c19ivm.org/meta.html

Improv -ement

No. No. Studies Patients

page30image714965200 page30image714965408

All Studies 62%

99 137,255

  • Statistically significant lower risk is seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 60 studies from 54 independent teams in 24 different countries show statistically significant improvements.

  • Meta analysis using the most serious outcome shows 62% [51-70%] and 85% [77-90%] lower risk for early treatment and prophylaxis, with similar results for higher quality studies, primary outcomes, peer- reviewed studies, and for RCTs.

  • Results are very robust — in worst case exclusion sensitivity analysis 62 of 99 studies must be excluded to avoid finding statistically significant efficacy.

  • Pharmacokinetics show significant inter-individual variability Guzzo. Efficacy may vary depending on the manufacturer Williams.

  • Over 20 countries adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.

page30image513446576

Mortality 49%

ICU Admission 38%

51 122,827

page30image714965616

13 24,089

page30image714965824

Recovery 43%

Peer-reviewed 61%

35 7,837

page30image714966032

Viral Clearance 42%

30 4,157

page30image714966240

83 125,940

page30image714966448

Early Treatment 62%

37 57,715

page30image714966656 page30image714966864 page30image714967072

------- after exclusions

0 0.5 1.0 1.5+ Favors Favors Ivermectin Control

page31image194544960page31image714931440

https://c19ivermectin.com/isummary.png

Ivermectin for COVID-19: real-time meta analysis of 99 studies

page32image714297616

https://c19ivm.org/meta.html

page33image194549328

LOC

h

KDOWN CRIMES

page34image714546080

May, 16, 2021

page34image714546288

https://www.realclearmarkets.com/articles/2021/05/14/the_world_health_organization_endorses_lockdowns_forever_777027.html

page35image194554592

The following graph was produced by UK Column and demonstrates the lack of correlation between lockdown and "saving lives"

https://www.ukcolumn.org/article/who-controls-british-government-response-covid19-part-one

page36image714207008page36image714208048page36image714208256

Measures

Isolation

Quarantine of exposed individuals

Entry and exit screening

Border closures

Contact tracing

Internal travel restrictions

Workplace measures and closures

2019 Non-Pharmaceutical Interventions (NPI) for pandemic countermeasures

page36image714208464 page36image714208672 page36image714208880 page36image714209088page36image714209296 page36image714209504 page36image194586016

Guidelines and Actions

page36image714210128 page36image714210336

Voluntary isolation at home of sick individuals

Home quarantine of exposed individuals to reduce transmission is not recommended because there is no obvious rationale for this measure

Entry and exit screening for infection in travellers is not recommended, because of the lack of sensitivity of these
Measures. Nor recommended

Border closure is generally not recommended

Not recommended in general because there is no obvious rationale for it

Evidence

Very low

Very low (lack of effectiveness in reducing influenza transmission)

Very low

Very low (unknown)

Recommendations

At all times

2019

page36image714210544 page36image714210752page36image714210960 page36image714178560 page36image714178768page36image714178976

Very low (variable effectiveness)

page36image714179184 page36image714179392

Not recommended in any circumstances

page36image714179600 page36image714179808 page36image714180016

In 2019

page36image714180224 page36image714180432 page36image714180640page36image714180848 page36image714181056 page36image714181264

Conditionally recommended

Very low

page36image714181472 page36image714181680

Very low

Only under extraordinary circumstances

page36image714181888 page36image714182096 page36image714182304

School measures and closures

page36image714182512 page36image714182720

Avoiding crowding

Face masks

Teleworking from home, staggering shifts

Increasing desk spacing, reducing mixing between classes

Increase the distance and reduce the density among populations

No evidence that this is effective in reducing transmission

Very low (variable effectiveness)

Very low (unknown)

Moderate

https://apps.who.int/iris/bitstream/handle/10665/329438/9789241516839-eng.pdf?ua=1

page36image714183344 page36image714183552 page36image714183760 page36image714183968 page36image714184176page36image714184384 page36image714184592page36image714184800page36image714185008page36image714185216page36image714185424page36image714185632page36image714185840page36image714186048page36image714186256page36image714186464
page37image194512976

We shall never forget!!!

We shall never forget!!!

We shall never forget!!!

We shall never forget!!!

We shall never forget!!!

We shall never forget!!!

We shall never forget!!!

page38image194523168page38image194522608

“...now we have to go back into families find those people who are sick and remove them and isolate them...”

Dr Michael J. Ryan

Executive Director of the World Health Organization's Health Emergencies Programme

page39image194610832

Then there are the ...

VACCINES

i

page39image714083376 page39image714083584 page39image714083792 page39image194612624page39image194619008 page39image714085040 page39image714085248 page39image714085456
page40image194609936

The Perpetual LIE

page41image194930864page41image716108384page41image716108592

No one is safe, until everyone is safe

page41image716108800

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator

page41image716109424

Total Value Commitment

Access to COVID-19 Tools (ACT) Accelerator

$226 million

page41image194933216

GAVI COVAX AMC $156 million World Health Organisation $751 million

Coalition for Epidemic Preparedness Innovations CEPI)

$275 million

UNICEF

$150 million

Gates Foundation funding/investment in Covid Vaccine Candidates: Conflicts of Interest

Company

Covid Vaccine Candidate

Type

Value Investment (US$)

Pfizer/BioNTech

BNT162b2 mRNA

To develop mRNA-based vaccines for infectious diseases

$27,500,000 (July 2022) $100,000,000 (May 2022) $4,918,943 (BioNTech 2020) $17,252,854 (2016)

AstraZeneca

ChAdOx1 nCov-19

Develop COVID-19 DNA vaccine

$750 million (2020)(20)

ModernaTX, Inc.

mRNA-1273
(BMGF non-exclusive license)

To develop mRNA-based vaccines for infectious diseases

$100 million (future projects upto 2022) $1,051,128 (2019)
$19,984,859 (2016)

Novavax

NVX-CoV2373

Purified protein antigen Vaccine development

$15 million (2020)
$388 million (2020)(CEPI) $89 million

CureVac

CVnCoV

mRNA coronavirus vaccine

$52 million (27)

Icosavax Inc.

IVX-411

Develop COVID-19 vaccine

$10 million (2020)

Inovio Pharmaceuticals

INO-4800

Develop COVID-19 DNA vaccine

$5 million (2020)

Vir Biotechnology, Inc.

HIV vaccine development

$10,000,000 (2022) $10,034,896 (2021)

Merck

Molnupiravir

Antiviral drug

$120 million (2021)

page43image194731680
page44image715132368

Total Contributions (2020-2021)

Country/ Foundation

Total Contribution

Percentage

Germany

$1268 million

21.7%

Gates Foundation/ Gavi

$1183 million

20.3%

USA

$693 million

11.9%

Total

$5840.4 million

https://www.who.int/about/funding/contributors

WHO: Influence of the Gates Foundation

10

page44image715136112

j

Adverse Events...
...Following Immunization

(AEFI)

page45image194533952 page45image715218656page45image715218864page45image715219072

WHO & Pfizer Crimes & Corruption

page46image194623040page46image194614416page46image715543424page46image715543632

https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines

WHO & Pfizer Crimes & Corruption

BNT162b2
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

REF: FDA-CBER-2021-5683-0000054

page47image715384992 page47image715385200 page47image715385408 page47image715385616page47image715385824

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

page47image194596128page47image715386448 page47image715386656 page47image715386864 page47image715387072

9 pages of AEFI’s (Total 139 888) unreported by

Pfizer and WHO

page47image715387280 page47image715387488 page47image715387696 page47image194595904

https://archive.org/details/cumulative-analysis-of-post-authorization-adverse-event-reports-of-pf-07302048-bnt162b2

WHO & Pfizer Crimes & Corruption

BNT162b2
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

REF: FDA-CBER-2021-5683-0000054

page48image715442208

Adverse Events Following Immunization (AEFI’s) reported

The System Organ Classes (SOCs) that contained the greatest number (≥2%) of events, in the overall dataset, were General disorders and administration site conditions (51,335 AEs), Nervous system disorders (25,957), Musculoskeletal and connective tissue disorders (17,283), Gastrointestinal disorders (14,096), Skin and subcutaneous tissue disorders (8,476), Respiratory (Covid-19 - 1927, 4.6%), thoracic and mediastinal disorders (8,848), Infections and infestations (4,610), Injury, poisoning and procedural complications (5,590), and Investigations (3,693)

Limited Listed AEFI’s

Suddenunexplained death in epilepsy

Myocarditis post infection

Myocardial infarction

Pericarditis

Pericarditis lupus Guillain-Barre syndrome

COVID-19 pneumonia

Total: 139 888 AEFI’s
Approx 82 000 Serious AEFI’s (58%)

https://archive.org/details/cumulative-analysis-of-post-authorization-adverse-event-reports-of-pf-07302048-bnt162b2

Pfizer & WHO Crimes & Corruption

BNT162b2
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

REF: FDA-CBER-2021-5683-0000054

page49image781871472

Serious Red Flags

Outcomes

Excluded

7%

Deaths

3%

Excluded

22%

https://archive.org/details/cumulative-analysis-of-post-authorization-adverse-event-reports-of-pf-07302048-bnt162b2

New Pfizer data dump. Read it for yourself. 1 child was born alive out of 270. 238 out due to "reasons unknown" Safe and effective.

page50image781957552

The WHO – Covid Vaccine Adverse Event

page51image194607888 page51image194601728 page51image781771088page51image194605984

https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-2138820?lang=en

No comments:

Post a Comment